Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients

References

• Ahlqvist J, Fotheringham J, Akhyani N, Yaoo K, Fogdell Hahn A, Jacobson. Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. J NeurVirol 2005; 11: 384–394
   Web of Science ®Google Scholar
• Alvarez-Lafuente R, Martín-Estefanía C, De las Heras V, Castrillo C, Cour I, Picazo J J, Varela de Seijas E, Arroyo R. Prevalence of herpesvirus DNA in MS patients and healthy blood donnors. Acta Neurol Scand 2002a; 105: 95–99
   Google Scholar
• Alvarez-Lafuente R, Martín-Estefanía C, De las Heras V, Castrillo C, Picazo J J, Varela E, Arroyo R. Active human herpesvirus 6 infection in patients with multiple sclerosis. Arch Neurol 2002b; 59: 929–933
   Google Scholar
• Avolio C, Filippi M, Tortorella C, Rocca M A, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, Livrea P, Trojano M. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005; 11: 441–446
   PubMed Web of Science ®Google Scholar
• Cermelli C, Berti R, Soldan S S, Mayne M, D'ambrosia J M, Ludwin S K, Jacobson S. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis 2003; 187: 1377–1387
   Google Scholar
• Challoner P B, Smith K T, Parker J D, MacLeod D L, Coulter S N, Rose T M, Schultz E R, Bennett J L, Garber R L, Chang M, Schad P A, Stewart P M, Nowinski R C, Brown P B, Burmer G C. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995; 92: 7440–7444
   PubMed Web of Science ®Google Scholar
• Chapenko S, Millar A, Nora Z, Logina I, Kukaine R, Murovska M. Correlation between HHV-6 reactivation and multiple sclerosis disease activity. J Med Virol 2003; 69: 111–117
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Reindl M, Harvey J. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239–1243
   PubMed Web of Science ®Google Scholar
• European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–1497
   PubMed Web of Science ®Google Scholar
• Gilli F, Bertolotto A, Sala A, Hoffman F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg R LP, Leppert D. Neutralizing antibodies against IFN-β in multiple sclerosis: antagonization of IFN-β -mediated supp suppression of MMPs. Brain 2004; 127: 259–268
   PubMed Web of Science ®Google Scholar
• Gilli F, Sala A, Bancote C, Salacone P, Gallo M, Gaia E, Bertolotto A. Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients. J Immunol Methods 2002; 262: 187–190
   Google Scholar
• Giovannoni F, Munschauer E, 3rd, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 465–469
   PubMed Web of Science ®Google Scholar
• Hickey W F, Hsu B L, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254–260
   PubMed Web of Science ®Google Scholar
• Higashikata T, Yamagishi M, Sasaki H, Minatoya K, Ogino H, Ishibashi-Ueda H, Hao H, Nagaya N, Tomoike H, Sakamoto A. Application of real-time RT-PCR to quantifying gene expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human abdominal aortic aneurysm. Atherosclerosis 2004; 177: 353–360
   PubMed Web of Science ®Google Scholar
• Hong J, Tejada-Simón M V, Rivera V M, Zang Y CQ, Zhang J Z. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult scler 2002; 8: 237–242
   PubMed Web of Science ®Google Scholar
• Hymas W, Stevenson J, Taggart E W, Hillyard D. Use of lyophilized standards for the calibration of a newly developed real time PCR assay for human herpes type six (HHV6) variants A and B. J Virol Methods 2005; 143–150
   Google Scholar
• Jordan R C, Macabeo-Ong M, Shiboski C H, Dekker N, Gininger D G, Wong D T, Schmidt B L. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res 2004; 10: 6460–6465
   PubMed Web of Science ®Google Scholar
• Lee M A, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999; 122: 191–197
   PubMed Web of Science ®Google Scholar
• Lepert D, Lindberg R L, Kappos L, Leib S L. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev 2001; 36: 249–257
   Google Scholar
• Medeiros M, Sharma V K, Ding R, Yamaji K, Li B, Muthukumar T, Valderde-Rosas S, Hernandez A M, Muñoz R, Suthanthiran M. Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J Immunol Methods 2003; 279: 135–142
   PubMed Web of Science ®Google Scholar
• Myhr K M, Ross C, Nyland H I, Bendtzen K, Vedeler C A. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Neurology 2000; 55: 1569–1572
   PubMed Web of Science ®Google Scholar
• Opdenakker G, Van den Steen P E, Dubos B, Nelissen I, Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851–859
   PubMed Web of Science ®Google Scholar
• Pachner A R, Bertolotto A, Deisenhammer F. Measurement of MxA or protein as a biomarker of IFNβ bioactivity. Neurology 2003; 61: S24–S26, (Suppl 5)
   Google Scholar
• Pachner A R, Dail D, Pak E, Narayan K. The importance of measuring IFN-β antibodies bioactivity: Monitoring in MS patients and the effect of anti-IFN-β antibodies. J Neuroimmunol 2005; 166: 180–188
   PubMed Web of Science ®Google Scholar
• Pachner A R, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7: 17–25
   PubMedGoogle Scholar
• Panitch H, Goodin D S, Francis G, Chang P, Coyle P K, O'Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group. Evidence of Interferon Dose-response: European North American Comparative Efficacy, University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS. Neurology 2002; 59: 1496–1506
   PubMed Web of Science ®Google Scholar
• Raine C S, Canella B, Duijvestijn A M, Cross A H. Homing to central nervous system vasculature by antigen-specific lymphocytes.II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest 1990; 63: 476–89
   PubMed Web of Science ®Google Scholar
• Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001; 58: 1297–8
   PubMed Web of Science ®Google Scholar
• Ross C, Clemmesen K M, Svenson M. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48: 706–712
   PubMed Web of Science ®Google Scholar
• Rudick R A, Simonian N A, Alam J A. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266–1272
   PubMed Web of Science ®Google Scholar
• Sorensen P S, Ross C, Clemmesen K M, Bendtzen K, Frederiksen J L, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184–1191
   PubMed Web of Science ®Google Scholar
• Suhayl D J. Mechanism of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58: S3–S9
   Google Scholar
• Tejada-Simon M V, Zang Y CQ, Hong J, Rivera V M, Zhang J Z. Cross-reactivity with myelin basic protein and human-herpesvirus-6 in multiple sclerosis. Ann Neurol 2003; 53: 189–97
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889–894
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 2005; 45: 1277–1285
   Google Scholar
• Waubant E., Goodkin D., Bostrom A., Bacchetti P., Hietpas J., Lindberg R., Leppert D. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003; 60: 52–57
   PubMed Web of Science ®Google Scholar
• Yong V W, Krekoski C A, Forsyth P, Bell R, Edwards D R. Matrix metalloproteases and disease of the CNS. Trends Neurosci 1998; 21: 75–80
   PubMed Web of Science ®Google Scholar